Results for "HARMONi-2 Study"

Clinical trial results indicate that Summit Therapeutics’ investigational drug ivonescimab meets key secondary endpoints for overall survival in non-small cell lung cancer patients. The promising interim data positions the treatment as a potential new standard in first-line therapy.

An interim analysis of the Phase III HARMONi-2 study reveals that ivonescimab meets key secondary endpoints for overall survival, demonstrating clinically meaningful benefits compared to pembrolizumab in first-line PD-L1-positive non-small cell lung cancer patients.